The review identified a significant body of evidence supporting the use of SGLT2 inhibitors for cardiovascular risk reduction, particularly in terms of reducing the incidence of myocardial infarction, stroke, and cardiovascular death. The gene discussed is SLC5A2; the disease is Stroke.